Studying therapeutic effects of Methylprednisolone Acetate and Lidocaine injection in patients with Fibromyalgia

Studying the therapeutic effects of Methylprednisolone Acetate and lidoaine injection at GB-20 acupuncture point compared to oral Duloxetine in patients with Fibromyalgia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210308050630N1

Enrollment

Registered

2021-06-10

Start date

2021-03-09

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia. Fibromyalgia

Interventions

Intervention 1: Intervention group: for this group only once injection of the mixture of Methylprednisolone acetate and Lidocaine 2% will be performed ,to each GB-20 accupoint ,each side 3 cc with ne

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: patient diagnosed with fibromyalgia base on American College of Rheumatology guideline. Completing and signing the conscious consent form Abdominal pain, depression and headache for the last 6 mounths. pain in dfferent parts of body like Neck-Jaw-Shoulder-upper Arm-lower Arm-Chest-Abdomen-Back-upper Thigh at both sides of the body for the last week problems like weakness ,after sleep fatigue, impaired thought and memory for the last week

Exclusion criteria

Exclusion criteria: Patients with Diabetes mellitus-Thyroid disease-Neuropathy-Lyme disease-Hepatitis patients who use medications like ASA-Metoclopramide-Tamoxiphen-TCA-alfa agonists-Beta cyprotrone uncontroled mental illness

Design outcomes

Primary

Measure	Time frame
Body pain. Timepoint: Before treatment-2-4-8 weeks later. Method of measurement: Visual Analogue Scale.	—

Secondary

Measure	Time frame
Functional status. Timepoint: Before treatment -2-4-8 weeks after treatment. Method of measurement: FIBROMYALGIA IMPACT QUESTIONNAIRE (FIQ ).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNavid Ahmadi

Shiraz University of Medical Sciences

dr.navidahmadi.pmr@gmail.com+98 71 3230 9473

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026